Mesenchymal stem cells in hematopoietic stem cell transplantation

被引:176
作者
Battiwalla, Minoo [3 ]
Hematti, Peiman [1 ,2 ]
机构
[1] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA
[2] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI USA
[3] Roswell Pk Canc Inst, Dept Med, New York, NY USA
关键词
bone marrow transplantation; engraftment; graft-versus-host disease; hematopoietic stem cells; mesenchymal stem cells; mesenchymal stromal cells; VERSUS-HOST-DISEASE; HUMAN ADIPOSE-TISSUE; AMYOTROPHIC-LATERAL-SCLEROSIS; UMBILICAL-CORD BLOOD; HEMATOLOGIC MALIGNANCY PATIENTS; BONE-MARROW-TRANSPLANTATION; EX-VIVO EXPANSION; STROMAL CELLS; CLINICAL-TRIALS; OSTEOGENESIS IMPERFECTA;
D O I
10.1080/14653240903193806
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Mesenchymal stromal/stem cells (MSC) of bone marrow (BM) origin not only provide the supportive microenvironmental niche for hematopoietic stem cells (HSC) but are capable of differentiating into various cell types of mesenchymal origin, such as bone, fat and cartilage. In vitro and in vivo data suggest that MSC have low inherent immunogenicity, modulate/suppress immunologic responses through interactions with immune cells, and home to damaged tissues to participate in regeneration processes through their diverse biologic properties. MSC derived from BM are being evaluated for a wide range of clinical applications, including disorders as diverse as myocardial infarction and newly diagnosed diabetes mellitus type 1. However, their use in HSC transplantation, either for enhancement of hematopoietic engraftment or for treatment/prevention of graft-versus-host disease, is far ahead of other indications. Ease of isolation and ex vivo expansion of MSC, combined with their intriguing immunomodulatory properties and their impressive record of safety in a wide variety of clinical trials, make these cells promising candidates for further investigation.
引用
收藏
页码:503 / 515
页数:13
相关论文
共 88 条
[1]   Immunomodulation by mesenchymal stem cells - A potential therapeutic strategy for type 1 diabetes [J].
Abdi, Reza ;
Fiorina, Paolo ;
Adra, Chaker N. ;
Atkinson, Mark ;
Sayegh, Mohamed H. .
DIABETES, 2008, 57 (07) :1759-1767
[2]  
Anker PSI, 2003, HAEMATOLOGICA, V88, P845
[3]   Failure of adult marrow-derived stem cells to generate marrow stroma after successful hematopoietic stem cell transplantation [J].
Awaya, N ;
Rupert, K ;
Bryant, E ;
Torok-Storb, B .
EXPERIMENTAL HEMATOLOGY, 2002, 30 (08) :937-942
[4]   Cotransplantation of ex vivo-expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation [J].
Ball, Lynne M. ;
Bernardo, Maria Ester ;
Roelofs, Helene ;
Lankester, Arjan ;
Cometa, Angela ;
Egeler, R. Maarten ;
Locatelli, Franco ;
Fibbe, Willem E. .
BLOOD, 2007, 110 (07) :2764-2767
[5]   Autologous mesenchymal stem cell transplantation in stroke patients [J].
Bang, OY ;
Lee, JS ;
Lee, PH ;
Lee, G .
ANNALS OF NEUROLOGY, 2005, 57 (06) :874-882
[6]   Prophylaxis of acute GVHD: manipulate the graft or the environment? [J].
Barrett, A. John ;
Le Blanc, Katarina .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2008, 21 (02) :165-176
[7]   Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment [J].
Bensidhoum, M ;
Chapel, A ;
Francois, S ;
Demarquay, C ;
Mazurier, C ;
Fouillard, L ;
Bouchet, S ;
Bertho, JM ;
Gourmelon, P ;
Aigueperse, J ;
Charbord, P ;
Gorin, NC ;
Thierry, D ;
Lopez, M .
BLOOD, 2004, 103 (09) :3313-3319
[8]   Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood [J].
Bieback, K ;
Kern, S ;
Klüter, H ;
Eichler, H .
STEM CELLS, 2004, 22 (04) :625-634
[9]   Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials [J].
Brooke, Gary ;
Rossetti, Tony ;
Pelekanos, Rebecca ;
Ilic, Nina ;
Murray, Patricia ;
Hancock, Sonia ;
Antonenas, Vicki ;
Huang, Gillian ;
Gottlieb, David ;
Bradstock, Ken ;
Atkinson, Kerry .
BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (04) :571-579
[10]   BM-derived cell therapies for cardiovascular disease [J].
Cannon, R. O., III ;
Dunbar, C. E. .
CYTOTHERAPY, 2007, 9 (04) :305-315